Corbus unveils new data on its ADC Bladder cancer treatment

CAR-T Digest - August 2020

1 June 2024: Corbus unveils new data on its ADC Bladder cancer treatment

Corbus Pharmaceuticals is the second top-performing biotech stock of the year due to investor interest in its ADC candidate, CRB-701
CRB-701 is seen as potentially better tolerated than Padcev, which Pfizer acquired for $43 billion through its Seagen deal
In an early dose-finding study, CRB-701 showed a 28% overall response rate among 25 evaluable patients
Among 15 patients treated with three active doses, the overall response rate was 40%, with all responses being partial tumor shrinkage
All responses seen in bladder cancer (where Padcev is approved) were also observed in cervical cancer. This data was recently presented at ASCO